Carcinogenicity study of gamma-oryzanol in B6C3F1 mice.
The carcinogenic potential of gamma-oryzanol, a drug mainly used for the treatment of hyperlipidaemia, was studied in B6C3F1 mice. Groups of 50 males and 50 females were fed a diet containing 0 (control), 200, 600 or 2000 mg gamma-oryzanol/kg body weight/day for 78 wk. No treatment-related changes were observed in general condition, body weight, food consumption, mortality, organ weight or haematology. Histopathological examinations showed various tumours in all groups, including the control group. In the control and 2000-mg/kg groups, relatively high tumour incidences were observed in the liver of males and in the haematopoietic organs of females. However, there was no statistically significant difference in the incidence of any tumours between the control and the 2000-mg/kg groups. The findings indicate that under the experimental conditions described gamma-oryzanol was not carcinogenic in B6C3F1 mice.
Tamagawa
M
M
Department of Toxicology, Otsuka Pharmaceutical Co. Ltd, Tokushima, Japan.
Otaki
Y
Y
Takahashi
T
T
Otaka
T
T
Kimura
S
S
Miwa
T
T
D000284:Administration, Oral; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002273:Carcinogens / Q000008:administration & dosage / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005260:Female; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000633:toxicity*; D008297:Male; D051379:Mice; D009374:Neoplasms, Experimental / Q000139:chemically induced*; D009929:Organ Size / Q000187:drug effects; D010666:Phenylpropionates / Q000008:administration & dosage / Q000633:toxicity*
D002273:Carcinogens; D000960:Hypolipidemic Agents; D010666:Phenylpropionates; C013172:gamma-oryzanol